98%
921
2 minutes
20
Objective: To clarify the phenotypic spectrum and incidence of TRPV4 mutations in patients with inherited axonal neuropathies.
Methods: We screened for TRPV4 mutations in 169 French unrelated patients with inherited axonal peripheral neuropathy. Ninety-five patients had dominant Charcot-Marie-Tooth type 2 (CMT2) disease, and 74 patients, including 39 patients with distal hereditary motor neuropathy, 14 with congenital spinal muscular atrophy and arthrogryposis, 13 with CMT2, and 8 with scapuloperoneal spinal muscular atrophy, presented with additional vocal cord paralysis and/or skeletal dysplasia.
Results: No deleterious TRPV4 mutation was identified in the 95 patients with "pure" CMT2 (0/95). In contrast, 12 of 74 patients (16%) with neuropathy and vocal cord paralysis and/or skeletal dysplasia presented pathogenic TRPV4 mutations, including 7 patients with distal hereditary motor neuropathy, 2 with scapuloperoneal spinal muscular atrophy, 2 with congenital spinal muscular atrophy and arthrogryposis, and one with CMT2. Investigation of affected relatives allowed us to study 17 patients. All patients had childhood-onset motor neuropathy and showed a variety of associated findings, including foot deformities (100% of cases), kyphoscoliosis (100%), elevated serum creatine kinase levels (100%), vocal cord paralysis (94%), scapular winging (53%), respiratory insufficiency (29%), hearing loss (24%), skeletal dysplasia (18%), and arthrogryposis (12%). Eight missense mutations were observed in these 12 families, including 2 previously unreported. Six mutations were de novo events, and 2 asymptomatic carriers were identified.
Conclusion: With 16% of patients affected in our series, this study demonstrates that TRPV4 mutations are a major cause of inherited axonal neuropathy associated with a large spectrum of additional features.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1212/WNL.0000000000000450 | DOI Listing |
ACS Omega
September 2025
Neuroscience and Ageing Biology Division, CSIR- Central Drug Research Institute (CDRI), Lucknow 226031, India.
The TRPA1 channel has recently emerged as a critical target for pain relief since its antagonists target the beginning of the pain transduction pathway and, thus, are devoid of side effects such as sedation, dizziness, somnolence, or cognitive impairment. Despite this clinical significance, currently, no TRPA1 inhibitors suitable for therapeutic usage exist to target these channels. Since ancient times, natural products have been known to be a rich source of new drugs, useful therapeutic agents, as well as pharmacological tools.
View Article and Find Full Text PDFIndian J Nephrol
January 2025
Department of Nephrology, All India Institute of Medical Sciences, Nagpur, India.
JBMR Plus
September 2025
Section on Heritable Disorders of Bone and Extracellular Matrix, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, United States.
Osteogenesis imperfecta (OI) is a genetically heterogeneous connective tissue disorder with major findings of bone fragility and deformity and short stature. Most patients have dominant mutations in or . Heterozygous defects in transient receptor protein vanilloid 4 (), encoding a Ca permeable channel highly expressed in chondrocytes, osteoblasts, and osteoclasts, have been associated with skeletal dysplasias characterized by short stature, bone deformity, and osteoarthritis.
View Article and Find Full Text PDFMedicine (Baltimore)
April 2025
Department of Orthopedics, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Rationale: To observe the natural history of the disease and the radiographic evolution of growth and development in patients with metatropic dysplasia (MD) and to complement the spectrum of mutations in the transient receptor potential vanilloid 4 (TRPV4) gene and the spectrum of MD phenotypes.
Patient Concerns: We report a patient with MD caused by a novel missense mutation in TRPV4, who possessed a mixed phenotype of both abnormal skeletal development and peripheral neuropathy. From 3 months to the age of 7 years, we observed the patient's natural history and the imaging evolution of the patient's growth and development.
Genes Genomics
July 2025
Department of Biological Sciences, Kongju National University, 56 Gongjudaehak-ro, Gongju, 32588, Korea.
Background: Somatic mosaicism is caused by a postzygotic de novo mutation. It is a very rare genetic event, and mosaic cases have been reported only very limitedly among Korean patients with peripheral neuropathies, including Charcot-Marie-Tooth disease (CMT) so far.
Objective: This study was performed to identify and characterize somatic mosaicism in Korean families with CMT.